Drug & supplement interaction

Immunoaugmentative Therapy + ADO-Trastuzumab Emtansine

ADO-Trastuzumab Emtansine brand name: Kadcyla.

No Known Interaction
Medically reviewed by · Updated July 2026 · Pair last verified Sep 20, 2026
The bottom line No known interaction

We found no known interaction between Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone interested in this? Share
Facebook Post Reddit Email
On this page
Interaction report

Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between ADO-Trastuzumab Emtansine and Immunoaugmentative Therapy in our sources. This does not guarantee that the combination is completely free of risk — research on Immunoaugmentative Therapy alongside specific medications may be limited.

Worth understanding: our licensed dataset holds no drug-interaction record for Immunoaugmentative Therapy at all — not against ADO-Trastuzumab Emtansine, and not against any other medication we track. This verdict therefore rests on the absence of any recorded data, not on research that looked at this combination and found nothing. We cannot rule an interaction out.

Immunoaugmentative Therapy is a treatment rather than something you take. Tell whoever provides it which medicines you use, and ask your prescriber whether it is appropriate for your health and treatment. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Immunoaugmentative Therapy safety at a glance

Immunoaugmentative... overall Avoid IAT is unproven, not standardized, and carries infection and other risks; it is not recommended.
Pregnancy Avoid There is no safety data; avoid this unproven injectable therapy during pregnancy.
Breastfeeding Avoid No safety information exists; avoid while breastfeeding.

Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining ADO-Trastuzumab Emtansine and Immunoaugmentative Therapy? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
What to actually watch for

No Interaction Found — But Data Suggests Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so having Immunoaugmentative Therapy while taking the medicine can make those effects more likely to turn up, and harder to pin on one or the other if they do. 2 of them are worth acting on rather than waiting out — marked below.

  • Liver problems Worth acting on Additional detail

    Immunoaugmentative Therapy

    “Subcutaneously, serious infections, such as HIV and hepatitis B, have been reported after receiving immunoaugmentative therapy. This has raised the concern that the products used in therapy may be derived from infected individuals, without undergoing adequate sterilization processes.”

    Immunoaugmentative Therapy · Natural Medicines adverse-effect record, reported in hepatitis.

    2 sources cited
    1. 102928. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI
    2. 102929. Questionable Methods of Cancer Management: Immuno-augmentative Therapy (IAT). CA Cancer Journal for Clinicians1991;41(6):357-64.

    ADO-Trastuzumab Emtansine

    Listed in the ADVERSE REACTIONS section of the FDA label for ADO-Trastuzumab Emtansine. Read the label on DailyMed ›

  • A higher chance of infection Worth acting on Additional detail

    Immunoaugmentative Therapy

    “Immunoaugmentative therapy has never been thoroughly evaluated in clinical research. Case reports suggest that subcutaneous immunoaugmentative therapy can cause fatigue, flu-like illness, pain at the injection site, generalized pain, and swelling.”

    Immunoaugmentative Therapy · Natural Medicines adverse-effect record, reported in fatigue.

    3 sources cited
    1. 102927. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed
    2. 102928. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI
    3. 102929. Questionable Methods of Cancer Management: Immuno-augmentative Therapy (IAT). CA Cancer Journal for Clinicians1991;41(6):357-64.

    ADO-Trastuzumab Emtansine

    Listed in the ADVERSE REACTIONS section of the FDA label for ADO-Trastuzumab Emtansine. Read the label on DailyMed ›

  • Tiredness reported in 9.1% of FDA reports for ADO-Trastuzumab Emtansine Additional detail

    Immunoaugmentative Therapy

    “Subcutaneously, fatigue has been reported after immunoaugmentative therapy.”

    Immunoaugmentative Therapy · Natural Medicines adverse-effect record, reported in fatigue.

    1 source cited
    1. 102927. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed

    ADO-Trastuzumab Emtansine

    Listed in the ADVERSE REACTIONS section of the FDA label for ADO-Trastuzumab Emtansine, and in voluntary FDA adverse-event reports. Read the label on DailyMed ›

  • Swelling Additional detail

    Immunoaugmentative Therapy

    Recorded for Immunoaugmentative Therapy in the same Natural Medicines adverse-effect record shown under A higher chance of infection above.

    ADO-Trastuzumab Emtansine

    Listed in the ADVERSE REACTIONS section of the FDA label for ADO-Trastuzumab Emtansine. Read the label on DailyMed ›

Effects for ADO-Trastuzumab Emtansine come from the ADVERSE REACTIONS section of its FDA label; effects for Immunoaugmentative Therapy come from the Natural Medicines adverse-effect record, quoted above. Where a percentage is shown, it is the share of 8,277 voluntary FDA FAERS reports for ADO-Trastuzumab Emtansine that mention that effect — a reporting proportion, not an incidence rate and not evidence the drug caused it. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Overlapping uses

What ADO-Trastuzumab Emtansine Is Prescribed For, and What Immunoaugmentative Therapy Has Been Studied For

These two come up together because they touch the same health topic — not because they do the same job. ADO-Trastuzumab Emtansine is a prescription medicine with approved uses on its FDA label. Immunoaugmentative Therapy is a treatment: what follows is what researchers have looked at it for, and how strong that evidence is.

ADO-Trastuzumab Emtansine is prescribed for: Kadcyla (ado-trastuzumab emtansine) is used on its own to treat HER2-positive metastatic breast cancer in adults who have already received trastuzumab and a taxane chemotherapy, either together or separately. It is used when cancer has come back or spread, or when the disease returned within six months of finishing earlier treatment. Kadcyla is also used as adjuvant (after-surgery) treatment for HER2-positive early breast cancer in patients who still had remaining cancer after completing neoadjuvant (pre-surgery) treatment with a taxane and trastuzumab. Patients must be tested for HER2 overexpression or gene amplification using an FDA-authorized test before starting Kadcyla.

Immunoaugmentative Therapy has been studied for:

  • Cancer studied, not established Immunoaugmentative Therapy has been studied for this. Natural Medicines rates the evidence: Insufficient Reliable Evidence To Rate Read what the research shows

    Immunoaugmentative Therapy for cancer

    A retrospective evaluation of 46 cancer patients consecutively treated at an immunoaugmentative therapy clinic in Mexico suggests that this therapy does not alter the course of cancer or provide any measurable benefits. The validity of this finding is limited by the retrospective nature of the chart review.

    2 sources cited
    1. 102927. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed
    2. 102928. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI

Effectiveness ratings and the research summaries above are the verbatim record from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”. A rating below the top of that scale means researchers have looked at it — not that it works, and never that it can stand in for a prescribed medicine. Do not stop or replace ADO-Trastuzumab Emtansine on your own; if you are taking Immunoaugmentative Therapy for the same health topic, tell your prescriber, especially if the medicine is being adjusted to a target.

Everything else you take

See Every Supplement That Interacts With ADO-Trastuzumab Emtansine

This page covers Immunoaugmentative Therapy only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the ADO-Trastuzumab Emtansine page lists 121 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: Grapefruit (major), St. John's Wort (major), Acacia Rigidula (moderate), Adrafinil (moderate) and African Wild Potato (moderate).

By severity: 2 major · 87 moderate · 32 minor.

From our pharmacist’s overview on the ADO-Trastuzumab Emtansine page

“If you're taking ado-trastuzumab emtansine (Kadcyla) for HER2-positive breast cancer, treat this list as one to check carefully, not casually. Every one of the 121 flagged ingredients affects the same enzyme, CYP3A4, which your body uses to clear part of this medicine.”

Reviewed by 2 · Jul 18, 2026

Open the ADO-Trastuzumab Emtansine interaction page

How much people look this up

Where Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Immunoaugmentative Therapy
Steady interest

#935 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication ADO-Trastuzumab Emtansine
Top 10%

#143 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Immunoaugmentative Therapy reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 20, 2026. The Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine records this page draws on were last updated July 10, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Treatment approach

About Immunoaugmentative Therapy

What is Immunoaugmentative Therapy?

  • Cancer (as an alternative therapy)
  • Attempts to boost the immune system
  • Tumor reduction claims

Immunoaugmentative Therapy (IAT) is an unproven alternative cancer treatment, not a dietary supplement or herb. It involves injecting blood-derived protein mixtures, but there is no reliable scientific evidence that it treats cancer or any other disease, and it carries real safety risks. Talk to your oncologist before considering any alternative cancer therapy.

Not applicable (this is a treatment procedure, not a plant or herb) · Injections of blood-derived protein fractions given at a treatment clinic

An interaction check asks whether these two react with each other — it does not ask whether Immunoaugmentative Therapy is a good idea for someone in your situation. Here is what our Immunoaugmentative Therapy record says about it on its own.

Immunoaugmentative Therapy: dosing

There is no established or standardized dose for Immunoaugmentative Therapy, and it is not a product you can buy as a supplement. It was administered only at specific clinics following protocols that were never validated by mainstream science.HelloPharmacist does not recommend IAT.

From our Immunoaugmentative Therapy monograph — the full record covers uses, side effects and every documented interaction.

Read the full Immunoaugmentative Therapy monograph & all interactions
Medication

About Ado-trastuzumab Emtansine Injection

What Is Ado-trastuzumab Emtansine Injection Used For?

Brand name: Kadcyla

Kadcyla (ado-trastuzumab emtansine) is used on its own to treat HER2-positive metastatic breast cancer in adults who have already received trastuzumab and a taxane chemotherapy, either together or separately. It is used when cancer has come back or spread, or when the disease returned within six months of finishing earlier treatment.

Kadcyla is also used as adjuvant (after-surgery) treatment for HER2-positive early breast cancer in patients who still had remaining cancer after completing neoadjuvant (pre-surgery) treatment with a taxane and trastuzumab. Patients must be tested for HER2 overexpression or gene amplification using an FDA-authorized test before starting Kadcyla.

Most-Reported Side Effects for ADO-Trastuzumab Emtansine

From FAERS, the FDA’s public side-effect reporting system (8,277 reports, all brands). Reports are voluntary and are not proof the drug caused the effect.

Disease progression 781 reports
Fatigue 751 reports
Nausea 732 reports
Diarrhea 594 reports
Thrombocytopenia 468 reports
See full Ado-trastuzumab Emtansine Injection drug information
Keep checking

Other Drugs & Immunoaugmentative Therapy

Browse every other medication we’ve checked against Immunoaugmentative Therapy — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
0Moderate
0Minor
2,829No known interaction
2,829 No interaction
No interaction 2,829 drugs checked — show the list

We also checked Immunoaugmentative Therapy against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 2,829 medications checked with no known interaction — see the full Immunoaugmentative Therapy list.

See the full Immunoaugmentative Therapy interactions page
See every supplement checked against ADO-Trastuzumab Emtansine, ranked by severity
Evidence & sources

Immunoaugmentative Therapy References

The 3 references that drive our Immunoaugmentative Therapy monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed
  2. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI
  3. Questionable Methods of Cancer Management: Immuno-augmentative Therapy (IAT). CA Cancer Journal for Clinicians1991;41(6):357-64.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Having Immunoaugmentative Therapy While Taking ADO-Trastuzumab Emtansine: Common Questions

Is it safe to have Immunoaugmentative Therapy while taking ADO-Trastuzumab Emtansine?
We do not list a known interaction between Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine have any of the same side effects?
Yes — our sources link each of them separately to 4 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Are Immunoaugmentative Therapy and ADO-Trastuzumab Emtansine used for the same thing?
They overlap in purpose, which usually means the real question is whether you need both rather than whether they are safe together. This page lists the shared uses and how strong the evidence is for Immunoaugmentative Therapy in each. That is a conversation for your prescriber, especially if ADO-Trastuzumab Emtansine is being adjusted to a target.
Does ADO-Trastuzumab Emtansine interact with any supplements?
Yes. ADO-Trastuzumab Emtansine has documented interactions with 121 supplements in our database — Immunoaugmentative Therapy is not one of them. The ADO-Trastuzumab Emtansine interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Immunoaugmentative Therapy monograph Uses, safety profile, and every drug interaction in one place Ado-trastuzumab Emtansine Injection drug information The full plain-English guide to this medication ADO-Trastuzumab Emtansine supplement interactions Every supplement checked against ADO-Trastuzumab Emtansine, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 3 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About ADO-Trastuzumab Emtansine and Immunoaugmentative Therapy?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.